UK study checks real-world use of new VWD treatment

NCT ID NCT06433778

First seen Mar 23, 2026 · Last updated May 14, 2026 · Updated 9 times

Summary

This study looked back at medical records of 34 adults with von Willebrand disease (VWD) in the UK who received vonicog alfa (a lab-made clotting protein) to treat bleeding or prevent bleeding during surgery. The goal was to see how the drug was used in routine care and how well it worked. The study did not involve any new treatments or visits—it simply collected information that was already recorded.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Imperial College Healthcare

    London, W2 1NY, United Kingdom

  • Leeds Teaching Hospital

    Leeds, LS9 7TF, United Kingdom

  • Liverpool University Hospital

    Liverpool, L7 8XP, United Kingdom

  • Manchester University

    Manchester, M13 9WL, United Kingdom

  • Oxford University Hospital

    Oxford, OX3 9DU, United Kingdom

  • Royal Free London

    London, NW3 2QG, United Kingdom

  • University Hospitals Birmingham

    Birmingham, B15 2GW, United Kingdom

Conditions

Explore the condition pages connected to this study.